HOUSTON, June 03, 2026 – Hopstem Biotechnology, a clinical-stage biotech specializing in iPSC-derived cell therapeutics for neurological diseases, has secured the first Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for its proprietary iPSC-derived human forebrain neural progenitor cell injection, hNPC01. The candidate has displayed potential for treating persistent motor dysfunction due to basal ganglia ischemic stroke in phase I clinical study. [Read more…]
FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison
-
Site will serve as company’s new headquarters and expands capacity and capabilities for induced pluripotent stem cell development and manufacturing
-
New facility is part of a $200 million investment by Fujifilm in expanding research product and cell therapy manufacturing capabilities in the U.S. to support the growing global market
Madison, WI, May 19, 2026 – FUJIFILM Cellular Dynamics Inc., a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs), celebrated the opening of its new headquarters and iPSC development and manufacturing facility in its Madison home. The new site is expected to quadruple the capacity for the company’s iPSC-based research products and services manufacturing footprint and expand capabilities across FUJIFILM Cellular Dynamics’ research product portfolio. [Read more…]
Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
- Factor advances next-generation allogeneic and in vivo CAR-T cell therapy programs
- Presentations will include latest data from Factor’s IL12-expressing iMacrophages for treating solid tumors (FACT-112), as well as recent advances in Factor’s RNA-based cell reprogramming technologies
- Factor to reveal two novel iPSC-derived mesenchymal stem cell (iMSC) programs: Hypoimmune iMSCs for muscular dystrophy and HTRA1-expressing iMSCs for neurodegenerative disorders
Cord Blood Industry Consolidation Escalates in 2026
The global cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.
Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half.
Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, Asia, and Latin America. [Read more…]
Changing Dynamics in Umbilical Cord Blood and Tissue Banking in 2026
Cord blood is the blood that remains in the umbilical cord after the delivery of a newborn. It is a rich source of stem cells and immune system cells. During cord blood banking, these cells are isolated and cryopreserved for future use. The cells are collected from the two arteries and the vein which run along the length of the umbilical cord. The Wharton’s jelly is a gelatinous tissue that composes the umbilical cord, which also contains valuable therapeutic cells such as MSCs. [Read more…]
- 1
- 2
- 3
- …
- 335
- Next Page »